Overview
I have a track record of research in the field of haematological disorders, including red cell disorders and haematological malignancies. My work is primarily concerned with the development of molecular diagnostic methods for the NHS and the analysis of clinical trials samples.
Biography
Publications
2018
- Burnett, A. K. et al. 2018. Addition of the mammalian target of rapamycin inhibitor, Everolimus, to consolidation therapy in acute myeloid leukaemia: experience from the UK NCRI AML17 trial. Haematologica 103(10), pp. 1654-1661. (10.3324/haematol.2018.189514)
2014
- Campagna, D. R. et al. 2014. X-linked sideroblastic anemia due to ALAS2 intron 1 enhancer element GATA-binding site mutations. American Journal of Hematology 89(3), pp. 315-319. (10.1002/ajh.23616)
2011
- Kannengiesser, C. et al. 2011. Missense SLC25A38 variations play an important role in autosomal recessive inherited sideroblastic anemia. Haematologica 96(6), pp. 808-813. (10.3324/haematol.2010.039164)
2007
- Kingston, J., Bowen, D. J., Sweeney, M. C., Lawless, S., Jackson, H. and Worwood, M. 2007. Heteroduplex analysis for the three common HFE variants: methodology, reliablity and analysis of over 5000 requests for testing. Journal of Clinical Pathology 60(11), pp. 1244-1248. (10.1136/jcp.2006.042010)
2005
- Mills, K. I., Gilkes, A. F., Walsh, V., Sweeney, M. and Gale, R. 2005. Rapid and sensitive detection of internal tandem duplication and activating loop mutations of FLT3. British Journal of Haematology 130(2), pp. 203-208. (10.1111/j.1365-2141.2005.05589.x)
- Mills, K. I., Gilkes, A. F., Walsh, V., Sweeney, M., Austin, S. J. and Gale, R. E. 2005. FLT3 gene mutations in AML. British Journal of Haematology 129, pp. 29-29.
2004
- Gilkes, A. F., Walsh, V., Sweeney, M., Austin, S. J., Gale, R. E. and Mills, K. I. 2004. Rapid and quantitative detection of mutations of the FLT3 gene in AML. Blood 104(11), pp. 303A-303A.
2002
- Darley, R. L. et al. 2002. Protein kinase C mediates mutant N-Ras-induced developmental abnormalities in normal human erythroid cells. Blood 100(12), pp. 4185-92. (10.1182/blood-2002-05-1358)
2000
- Mills, K. I. et al. 2000. High FUS/TLS expression in acute myeloid leukaemia samples. British Journal of Haematology 108(2), pp. 316-321. (10.1046/j.1365-2141.2000.01883.x)
1999
- Mills, K. I., Woodgate, L., Gilkes, A. F., Walsh, V., Sweeney, M. C., Brown, G. and Burnett, A. K. 1999. Inhibition of mitochondrial function in HL60 cells is associated with an increased apoptosis and expression of CD14. Biochemical and Biophysical Research Communications 263(2), pp. 294-300. (10.1006/bbrc.1999.1356)
- Woodgate, L. J., Walker, E. J., Gilkes, A. F., Walsh, V., Sweeney, M. C., Mills, K. I. and Burnett, A. 1999. Lovastatin in combination with ATRA may be a potential therapy for leukaemia [Abstract]. British Journal of Haematology 105(Sup.), pp. 74.
1998
- Mills, K. I. et al. 1998. Identification of a retinoic acid responsive aldoketoreductase expressed in HL60 leukaemic cells. FEBS Letters 440(1-2), pp. 158-162. (10.1016/s0014-5793(98)01435-5)
My current research is concerned with the development of methods for the detection and analysis of tyrosine kinase mutations within the BcrAbl rearrangement. Identification of of mutations in patients at diagnosis and relapse will enable the optimal drug treatment for the patient to be selected.